Ocrelizumab for the treatment of multiple sclerosis-Reference-Cited by-同舟云学术

Ocrelizumab for the treatment of multiple sclerosis

Published:2018-12-28 Issue:2 Volume:19 Page:97-108
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Bigaut Kévin¹,De Seze Jérôme¹²³,Collongues Nicolas¹²³

Affiliation:

1. Département de Neurologie, Centre Hospitalier Universitaire de Strasbourg, Avenue Moliére, 67200 Strasbourg, France

2. Biopathologie de la Myéline,Neuroprotection et Stratégies Thérapeutiques, INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67000 Strasbourg, France

3. Centre d’investigation clinique, INSERM U1434, Centre Hospitalier Universitaire de Strasbourg, 1 Place de l'Hôpital, 67000 Strasbourg, France

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Clinical Neurology,General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2019.1561284

Reference67 articles.

1. Defining the clinical course of multiple sclerosis: The 2013 revisions

2. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin

3. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

4. B cells and multiple sclerosis

5. B cells in multiple sclerosis

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience;International Journal of Molecular Sciences;2024-05-14

2. Mapping the Therapeutic Options for Multiple Sclerosis in Brazil: A Comprehensive Analysis;Sclerosis;2024-02-06

3. An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis;Cureus;2023-01-02

4. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study;Multiple Sclerosis and Related Disorders;2023-01

5. Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation;Computational and Structural Biotechnology Journal;2023